Debt ceiling deal done? Here’s what’s next for bond ETF investors
With an agreement on the debt ceiling easing macro concerns, the aftereffects of avoiding default could pose new challenges for bond ETF investors.
What Tesla charging partnerships with Ford and GM mean for the EV industry
Ford Motor, General Motors and Tesla appear to have shifted the tide on the electric vehicle-charging infrastructure in North America.
Crypto tokens plunged this week after Gensler stepped up SEC crackdown
Several of the most valuable cryptocurrencies dropped more than 15% this week after the SEC filed lawsuits against Coinbase and Binance.
Watch live: DOJ special counsel Jack Smith speaks after Trump classified-records indictment is unsealed
Smith has been leading the Department of Justice investigation into the transfer of classified documents to Trump’s home Mar-a-Lago.
1 in 5 student loan borrowers at risk of struggling when payments resume, consumer watchdog says
The Consumer Financial Protection Bureau warns that 1 in 5 student loan borrowers have risk factors that could cause them to struggle when bills resume.
Layoffs hit Colorado space companies as funding remains tight
The layoffs came at Ursa Major, which makes rocket engines, and Orbit Fab, a startup aiming to provide refueling services to spacecraft.
Layoffs hit Colorado space companies as funding remains tight
The layoffs came at Ursa Major, which makes rocket engines, and Orbit Fab, a startup aiming to provide refueling services to spacecraft.
Apple Vision Pro: Impressive specs, new way of interacting could help it break the VR curse
Apple’s Vision Pro headset has sparked a resurgence of interest in virtual reality headsets.
Tesla on track to match its longest winning streak on heels of GM charging deal
The streak follows Tesla’s announcement Thursday that General Motors would join Ford in using its electric vehicle charging network to charge their cars.
FDA advisors endorse Alzheimer’s treatment Leqembi paving way for full approval this summer
Medicare has promised to broadly cover Leqembi, which costs $26,500 per year, if the FDA grants full approval of the treatment.
